Cargando…

The Promise of Novel Molecular Markers in Bladder Cancer

Bladder cancer is the fourth most common malignancy in the US and is associated with the highest cost per patient. A high likelihood of recurrence, mandating stringent surveillance protocols, has made the development of urinary markers a focus of intense pursuit with the hope of decreasing the burde...

Descripción completa

Detalles Bibliográficos
Autores principales: Miremami, Jahan, Kyprianou, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284796/
https://www.ncbi.nlm.nih.gov/pubmed/25535079
http://dx.doi.org/10.3390/ijms151223897
_version_ 1782351466684481536
author Miremami, Jahan
Kyprianou, Natasha
author_facet Miremami, Jahan
Kyprianou, Natasha
author_sort Miremami, Jahan
collection PubMed
description Bladder cancer is the fourth most common malignancy in the US and is associated with the highest cost per patient. A high likelihood of recurrence, mandating stringent surveillance protocols, has made the development of urinary markers a focus of intense pursuit with the hope of decreasing the burden this disease places on patients and the healthcare system. To date, routine use of markers is not recommended for screening or diagnosis. Interests include the development of a single urinary marker that can be used in place of or as an adjunct to current screening and surveillance techniques, as well identifying a molecular signature for an individual’s disease that can help predict progression, prognosis, and potential therapeutic response. Markers have shown potential value in improving diagnostic accuracy when used as an adjunct to current modalities, risk-stratification of patients that could aid the clinician in determining aggressiveness of surveillance, and allowing for a decrease in invasive surveillance procedures. This review discusses the current understanding of emerging biomarkers, including miRNAs, gene signatures and detection of circulating tumor cells in the blood, and their potential clinical value in bladder cancer diagnosis, as prognostic indicators, and surveillance tools, as well as limitations to their incorporation into medical practice.
format Online
Article
Text
id pubmed-4284796
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42847962015-01-21 The Promise of Novel Molecular Markers in Bladder Cancer Miremami, Jahan Kyprianou, Natasha Int J Mol Sci Review Bladder cancer is the fourth most common malignancy in the US and is associated with the highest cost per patient. A high likelihood of recurrence, mandating stringent surveillance protocols, has made the development of urinary markers a focus of intense pursuit with the hope of decreasing the burden this disease places on patients and the healthcare system. To date, routine use of markers is not recommended for screening or diagnosis. Interests include the development of a single urinary marker that can be used in place of or as an adjunct to current screening and surveillance techniques, as well identifying a molecular signature for an individual’s disease that can help predict progression, prognosis, and potential therapeutic response. Markers have shown potential value in improving diagnostic accuracy when used as an adjunct to current modalities, risk-stratification of patients that could aid the clinician in determining aggressiveness of surveillance, and allowing for a decrease in invasive surveillance procedures. This review discusses the current understanding of emerging biomarkers, including miRNAs, gene signatures and detection of circulating tumor cells in the blood, and their potential clinical value in bladder cancer diagnosis, as prognostic indicators, and surveillance tools, as well as limitations to their incorporation into medical practice. MDPI 2014-12-22 /pmc/articles/PMC4284796/ /pubmed/25535079 http://dx.doi.org/10.3390/ijms151223897 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Miremami, Jahan
Kyprianou, Natasha
The Promise of Novel Molecular Markers in Bladder Cancer
title The Promise of Novel Molecular Markers in Bladder Cancer
title_full The Promise of Novel Molecular Markers in Bladder Cancer
title_fullStr The Promise of Novel Molecular Markers in Bladder Cancer
title_full_unstemmed The Promise of Novel Molecular Markers in Bladder Cancer
title_short The Promise of Novel Molecular Markers in Bladder Cancer
title_sort promise of novel molecular markers in bladder cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284796/
https://www.ncbi.nlm.nih.gov/pubmed/25535079
http://dx.doi.org/10.3390/ijms151223897
work_keys_str_mv AT miremamijahan thepromiseofnovelmolecularmarkersinbladdercancer
AT kyprianounatasha thepromiseofnovelmolecularmarkersinbladdercancer
AT miremamijahan promiseofnovelmolecularmarkersinbladdercancer
AT kyprianounatasha promiseofnovelmolecularmarkersinbladdercancer